Microwave Ablation Combined With Chemotherapy for Colorectal Liver Metastases： a Multicenter Cohort Study

• Status: Not yet recruiting
• Trial end date: 2026-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Colorectal cancer is the second deadliest malignant tumor worldwide, and liver is the most common site of hematogenic metastasis of Colorectal cancer. Surgery is an effective treatment for colorectal cancer with liver metastasis, however, only 10%-20% of patients with liver metastasis are feasible for radical surgical resection. Many single-center retrospective studies have demonstrated that thermal ablation for liver metastases is comparable to surgery. Chemotherapy can kill the microscopic cancer foci of the liver. The timing of ablation-related chemotherapeutic administration still needs to be explained.

The purpose of this study was to compare the clinical efficacy of thermal ablation or combined with perioperative chemotherapy and postoperative chemotherapy in the treatment of colorectal cancer with liver metastasis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ping Liang

Criteria

Inclusion Criteria:

• 1) Aged between 18 and 80, WHO physical status score < level 2

• 2) Histologically confirmed colorectal cancer, liver metastasis (≤4), maximum diameter ≤4cm;

• 3) Patients without extrahepatic metastasis;

• 4) If the primary tumor has been resected or has metastasized at the same time, the multidisciplinary panel determines that the primary tumor can be resected and resected within one month after ablation;

• 5) No other chemotherapy experience except anti-tumor treatment for the primary cancer;

• 6) The main organs function normally, that is, they meet the following standards:

1. Blood routine examination: HB≥90 g/L; The ANC acuity 1.5 x 109 / L; PLT 60 x 109 / L or higher;

2. Biochemical examination: ALB ≥29g/L; ALT and AST < 3 uln; 1.5 ULN TBIL or less; Creatinine 1.5 or less ULN.

Exclusion Criteria:

• 1) A history of other malignant tumors in the past 5 years;

• 2) Cardiovascular diseases with significant clinical symptoms (uncontrolled congestive heart failure, angina pectoris, hypertension, arrhythmia);

• 3) Persons with coagulation disorders;

• 4) Combined with active infection;

• 5) Those with any contraindications related to chemotherapy;

• 6) Pregnant or lactating women;

• 7) A history of substance abuse and mental illness;

• 8) The investigator believes that there are any other factors that are not suitable for inclusion or affect the subject's participation in the study.